Andrew Hirsch — Chief Financial Officer at Agios Pharmaceuticals

Mr. Andrew Hirsch has been Chief Financial Officer at Agios Pharmaceuticals, Inc. since September 19, 2016. Mr. Hirsch served as the Chief Executive Officer and President of BIND Therapeutics, Inc. (now DNIB Unwind, Inc.) since March 10, 2015 until August 1, 2016. He served as the Chief Financial Officer of BIND Biosciences, Inc. (now DNIB Unwind, Inc.) since July 16, 2012 until March 2015, served as its Principal Accounting Officer and secretary until March 2015. He served as an Acting President of BIND Therapeutics, Inc. since March 2015. Mr. Hirsch served as the Chief Operating Officer of BIND Therapeutics, Inc. since February 15, 2014 until March 2015. He has nearly 20 years of financial leadership and strategic management experience. He served as the Chief Financial Officer of Avila Therapeutics, Inc. (now Celgene Avilomics Research, Inc.) since July 2011 until its acquisition by Celgene Inc. in March 2012. He served in roles of increasing responsibility during his nearly ten year tenure at Biogen Idec, as Vice President, Corporate Strategy and M&A. In addition, he served as Program Executive in neurology leading the development teams for the BG-12, Avonex and Tysabri programs. Mr. Hirsch led business development for a software start-up company and spent several years in management consulting at Stern Stewart & Co. and The Parthenon Group. He has been a Director of Editas Medicine, Inc. since May 31, 2017. He serves as a Director of The Boston Foundation for Sight, Inc. He served as a Director of DNIB Unwind, Inc. since June 2015. Mr. Hirsch graduated from the University of Pennsylvania with a Bachelor of Arts in Economics and holds a Masters of Business Administration from The Tuck School at Dartmouth College.